DKK157.90
0.06% today
Copenhagen, Nov 26, 01:17 pm CET
ISIN
DK0061802139
Symbol
ALK B
Sector
Industry

ALK-Abelló Stock price

DKK158.00
-7.90 4.76% 1M
+5.00 3.27% 6M
+56.80 56.13% YTD
+66.40 72.49% 1Y
+2.10 1.35% 3Y
+76.30 93.39% 5Y
+123.00 351.43% 10Y
Copenhagen, Closing price Mon, Nov 25 2024
-0.50 0.32%
ISIN
DK0061802139
Symbol
ALK B
Sector
Industry

Key metrics

Market capitalization DKK34.97b
Enterprise Value DKK34.92b
P/E (TTM) P/E ratio 44.54
EV/FCF (TTM) EV/FCF 42.18
EV/Sales (TTM) EV/Sales 6.49
P/S ratio (TTM) P/S ratio 6.50
P/B ratio (TTM) P/B ratio 6.88
Revenue growth (TTM) Revenue growth 13.85%
Revenue (TTM) Revenue DKK5.38b
EBIT (operating result TTM) EBIT DKK1.08b
Free Cash Flow (TTM) Free Cash Flow DKK828.00m
Cash position DKK556.00m
EPS (TTM) EPS DKK3.55
P/E forward 40.20
P/S forward 6.29
EV/Sales forward 6.28
Show more

Is ALK-Abelló a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ALK-Abelló Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ALK-Abelló forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a ALK-Abelló forecast:

Buy
75%
Hold
25%

Financial data from ALK-Abelló

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5,383 5,383
14% 14%
100%
- Direct Costs 1,941 1,941
10% 10%
36%
3,442 3,442
16% 16%
64%
- Selling and Administrative Expenses 1,591 1,591
9% 9%
30%
- Research and Development Expense 515 515
21% 21%
10%
1,336 1,336
57% 57%
25%
- Depreciation and Amortization 260 260
7% 7%
5%
EBIT (Operating Income) EBIT 1,076 1,076
77% 77%
20%
Net Profit 785 785
85% 85%
15%

In millions DKK.

Don't miss a Thing! We will send you all news about ALK-Abelló directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Peter Halling
Employees 2,824
Founded 1923
Website www.alk.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today